Lexogen and TATAA Biocentre have entered an agreement to distribute Lexogen’s NGS products and expand their market size in Europe.
Under the terms, TATAA Biocentre will be responsible for distribution of Lexogen’s NGS products in Sweden, Denmark, Norway, Germany, Aystria, France, Luxemberg, Slovakia and Czech Republic and incorporate Lexogen’s NGS products in its NGS training courses in various European locations.
The partnership enables Lexogen to expand the utility of NGS products in transcription analysis and RNA analysis tools to European end-users.
PerkinElmer and Genome Institute of Singapore (GIS) have formed a joint venture named PerkinEmler-GIS Centre to further develop precision oncology.
PerkinElmer and GIS will combine their cell-based research imaging technologies with cancer therapeutics, stratified oncology, stem cell biology, and regenerative medicine respectively, as part of the agreement.
The partnership enables both companies to develop insights of molecular mutation, biomarkers for patient stratification and further develop precision oncology.
Interprotein has entered an R&D agreement with A.I Squared to develop a novel pharmaceutical by combining the molecular designing technologies of the former and artificial intelligence technology of the latter to create a paradigm of new drug discovery.
The partnership enables Interprotein and A.I Squared analyse protein-protein interaction along with new drug discovery.
Hainan Haiyao has announced to raise funds of approximately $76.9m through private placement of medium-term notes. It has further announced that the placement will be subscribed to by institutional investors in China’s interbank bond market.
The company plans to use the gross proceeds for providing sufficient working capital.
Novacyt SA has announced to acquire Primerdesign through the funds raised from private placement of its 1,428,572 common stock shares. It has further announced that the placement will be subscribed to by current investors including Alto Invest at a price of $1.57 per share.
The company will raise gross proceeds of $2.24m through the offering.
FLX Bio has raised funds in a Series B venture financing round led by biotechnology and corporate venture capital investors, including The Column Group, Topspin Partners, Kleiner Perkins Caufield and Byers and Celgene Corporation.
The company plans to use the approximately $50m gross proceeds to advance the discovery and development of its immune-oncology drug pipeline, and also to develop FLX925, which is in Phase I clinical trials stage for patients with acute myeloid leukaemia.